WHO ICTRP trial
Characterization of aberrant immune response in post-COVID using innovative…
NL-OMON56864 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON56864 |
|---|---|
| Public title | Characterization of aberrant immune response in post-COVID using innovative signal transduction pathway technology (LC-STP) |
| Scientific title | Characterization of aberrant immune response in post-COVID using innovative signal transduction pathway technology (LC-STP) - Immune cell STP*s to characterize Long-COVID |
| Primary sponsor | Academisch Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational |
| Countries | Netherlands |
| Conditions | Long-COVID Post-COVID;10027665;10047438 |
| Registration date | Jul 4, 2024 |
| Target size | 50 |
| Secondary IDs | NL86227.078.24 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: